What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence for aficamten’s clinical effectiveness is robust, demonstrating significant improvements in key endpoints such as LVOT gradient reduction and exercise capacity compared to placebo in Phase 2 and Phase 3 trials. The pivotal SEQUOIA-HCM trial met its primary endpoint with a clinically meaningful increase in peak VO2, and all secondary endpoints were also met with high statistical significance. This indicates a clear clinical advantage over standard care.
Does the economic case hold at the expected price? — Cost effectiveness
Currently, there is no published cost-effectiveness analysis for aficamten, and the drug’s price is not yet known. Given the expected high cost based on similar therapies, it is likely that aficamten will face challenges in demonstrating cost-effectiveness without further economic evaluations.
Is there quality-of-life evidence payers weigh? — Quality of life
Aficamten’s trials utilized validated instruments like the Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure HRQoL, showing significant improvements at multiple time points. The evidence indicates that patients experience meaningful quality of life gains, although direct utility values are not available, which is a limitation for cost-effectiveness analysis.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Aficamten has shown an excellent safety profile in clinical trials, with adverse events comparable to placebo and no significant safety concerns reported. The incidence of serious adverse events was lower than that of placebo, indicating a favorable safety profile, especially in the context of a new cardiac therapy.
Was the drug compared against what payers expect? — Comparator Selection
The comparators used in aficamten’s clinical trials were appropriate and relevant, including placebo plus background therapy and an active comparator (metoprolol). This reflects current standard of care for obstructive HCM and strengthens the evidence’s applicability to real-world clinical practice.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations for aficamten were broadly representative of the target patient population with symptomatic obstructive HCM, including a mix of genders and ages. Subgroup analyses indicated consistent efficacy across various baseline characteristics, although certain groups like pediatric patients were not included.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Aficamten can be integrated into existing care pathways for HCM without requiring new diagnostic technologies. The treatment sequencing is logical, fitting well into the current management strategies for obstructive HCM, and the monitoring requirements are manageable.
Are the wider system costs understood? — Resource Use and Cost Implications
The introduction of aficamten is expected to incur substantial direct medical costs primarily due to the drug’s acquisition cost. While there may be some cost offsets from avoided surgeries, the overall financial impact on healthcare systems is likely to be significant, raising concerns about affordability.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence for aficamten is derived from well-designed clinical trials with high methodological rigor, including randomized controlled trials and a robust safety profile. The consistency of results across studies enhances the credibility of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While the short-term efficacy and safety of aficamten are well-demonstrated, there are uncertainties regarding long-term outcomes and the assumptions underlying cost-effectiveness analyses. These uncertainties could significantly impact the drug’s value proposition in real-world settings.
